Why the study?
The study was conducted to investigate the association among the PlA1/A2 gene polymorphism, laboratory aspirin resistance, and adverse clinical outcomes in coronary artery disease patients receiving aspirin maintenance therapy.
Does PlA1/A2 gene polymorphism or laboratory aspirin resistance predict adverse clinical outcomes in patients with coronary artery disease on aspirin maintenance therapy?
Does PlA1/A2 gene polymorphism or laboratory aspirin resistance predict adverse clinical outcomes in patients with coronary artery disease on aspirin maintenance therapy?
Laboratory aspirin resistance, but not PlA1/A2 gene polymorphism, predicts all-cause death and target vessel revascularization in CAD patients on aspirin therapy.
Answers are grounded in this paper and cite their sources.
Laboratory aspirin nonresponse signals higher death/TVR risk in CAD; confirms prognostic value while challenging PlA2 polymorphism utility for stratification.
The aim of this study was to investigate the association among the PlA1/A2 gene polymorphism, laboratory aspirin resistance and adverse clinical outcomes in coronary artery disease (CAD) patients who were on aspirin maintainance therapy. A comprehensive literature search was performed and 35 eligible clinical trials including 19025 CAD patients were recruited. Adverse clinical outcomes involving all-cause death, non-fatal myocardial infarction (MI), ischemic stroke and target vessel revascularization (TVR) were analyzed. The definition of aspirin resistance in each study was accepted. Meta-analysis was performed using the Review Manager 5.3.5 System. In CAD patients, the PlA2 gene carriers had similar incidence of laboratory aspirin resistance compared to those with PlA1/A1 genotype [29.7% vs 28.3%, OR = 0.94 (95% CI 0.63 to 1.40, P = 0.74)], and there were no significant differences in the adverse clinical outcomes between the PlA2 carriers and the PlA1/A1 genotype patients. However, the laboratory aspirin non-responders had higher risks of death [7.9% vs. 2.5%, OR = 2.42 (95% CI 1.86 to 3.15, P < 0.00001)] and TVR [4.5% vs. 1.7%, OR = 2.20 (95% CI 1.19 to 4.08, P = 0.01)] compared to the responders. In aspirin-treated CAD patients, the laboratory aspirin resistance predicts all-cause death and TVR. However, the PlA1/A2 gene polymorphism predicts neither the laboratory aspirin response nor the clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: